Introduction: Neuro-QoL is a multidimensional patient-reported outcome measurement system assessing aspects of physical, mental, and social health identified by neurology patients and caregivers as important. One of the first neurology-specific patient-reported outcome measure systems created using modern test development methods, Neuro-Qol enables brief, yet precise, assessment and the ability to conduct both PD-specific and cross-disease comparisons. We present results of Neuro-QoL clinical validation using a sample of PD patients.
Methods: A total of 120 PD patients recruited from academic medical centers were assessed at baseline, 1 week, and 6 months. Assessments included Neuro-QoL and general and PD-specific validity measures.
Results: Participants were 62% male and 95% white (average age = 66); H & Y stages were 1 (16%), 2 (61%), 3 (18%), and 4 (5%). Internal consistency and test-retest reliability of Neuro-QoL ranged from Cronbach's alphas = 0.81 to 0.94 with intraclass correlation coefficients = 0.66 to 0.80. Pearson's correlations between Neuro-QoL and legacy measures were generally moderate and in expected directions. UPDRS Part 2 was moderately correlated with Neuro-QoL Upper Extremity and Mobility, respectively (r's = -0.44; -0.59). Parkinson's Disease Questionnaire-39 and Neuro-QoL measures of similar constructs showed strong-to-moderate correlations (r's = 0.70-0.44). Neuro-QoL measures of fatigue, mobility, positive emotion, and emotional/behavioral control showed responsiveness to self-reported change.
Conclusions: Neuro-QoL is valid for use in PD clinical research. Reliability for all but two measures is sufficient for group comparisons, with some evidence supporting responsiveness to change. Neuro-QoL possesses characteristics, such as brevity, flexibility in administration, and suitability, for cross-disease comparisons that may be advantageous to users in a variety of settings. © 2016 Movement Disorder Society.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/mds.26546 | DOI Listing |
Mult Scler Relat Disord
December 2024
Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA. Electronic address:
It is debated whether seasonal variation in outside temperature contributes to MS fatigue, one of the disease's most common symptoms. We analyzed the effect of the season on the baseline fatigue levels in our randomized, placebo-controlled, crossover, double-blind trial, Treatment of Fatigue with Methylphenidate, Modafinil, and Amantadine in MS (TRIUMPHANT-MS) conducted in two sites with very different climates. Fatigue was measured using two validated instruments (Modified Fatigue Impact Scale (MFIS) and Neuro-QoL fatigue score).
View Article and Find Full Text PDFJ Neuropsychiatry Clin Neurosci
November 2024
University of Virginia School of Nursing, Charlottesville (Gibson, Jiang); Department of Neurology, Vanderbilt University Medical Center, Nashville (Hay, Claassen, McDonell, Brown, Wynn, Isaacs).
Objective: Apathy is common in Huntington's disease (HD) and difficult to treat. Multiple recent calls have been made to increase understanding of apathy across the spectrum of HD severity. Functional status is an important outcome in HD trials; however, no consensus currently exists regarding the impact of apathy on functional status in HD.
View Article and Find Full Text PDFAnn Hematol
November 2024
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
This study describes the health-related quality of life (HRQoL) and symptom-specific functional impairment of patients with paroxysmal nocturnal hemoglobinuria (PNH) in a real-world setting. US-based adults with PNH treated with a parenterally administered complement inhibitor (PACI) for ≥ 6 months completed an online, cross-sectional, observational survey; a subset of patients also participated in semi-structured qualitative interviews. The survey included the PROMIS 29 + 2 Profile v2.
View Article and Find Full Text PDFJ Am Podiatr Med Assoc
November 2024
*Department of Plastic and Reconstructive Surgery, MedStar Georgetown University Hospital, Washington, DC. Dr. Sayyed is now with SIU Institute for Plastic Surgery, Southern Illinois University School of Medicine, Springfield IL.
Background: Completion of patient-reported outcome measures (PROMs) is labor-intensive but paramount in improving patient-centered care, allowing for advancement of techniques and scrutinization of outcomes. We report the feasibility of PROM collection and reporting for patients seen in a high-volume, multidisciplinary, tertiary limb salvage center to determine pain and functionality outcomes.
Methods: The center received grant funding resources for large-scale PROM collection.
Brain
November 2024
Khondrion BV, 6534 AT Nijmegen, The Netherlands.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!